Yue Yang

发表

Assessment of the breakthrough-therapy-designated drugs granted in China: a pooled analysis 2020-2022.

Yanrong Li, Xingxian Luo, Feng Qian, 2022, Drug discovery today.

Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021

Xingxian Luo, Xin-Li Du, Feng Qian, 2022, Clinical pharmacology and therapeutics.

The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis

S. Chow, Yue Zhou, Xingxian Luo, 2022, The Lancet regional health. Western Pacific.

Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021

Xingxian Luo, Xin-Li Du, Jingshu Yang, 2022, Clinical pharmacology and therapeutics.

Evaluation of clinical trial designs for novel anticancer drugs in China: a cohort study of drugs approved between 2015 and 2021.

S. Chow, Xingxian Luo, Lin Huang, 2023, Drug discovery today.

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022

S. Chow, Jingwen Liu, Xingxian Luo, 2023, EClinicalMedicine.

Regulation of Generic Drugs in China: Progress and Effect of the Reform of the Review and Approval System

Mengsi Liu, Siyue Chen, Yue Yang, 2022, Journal of Pharmaceutical Innovation.

Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China

Xingxian Luo, Xin-Li Du, Xuecai Xue, 2023, JAMA network open.

A comparative analysis of vaccine lists, prices, and candidates, and the national immunization program between China and the United States

Xingxian Luo, Xin-Li Du, Yue Yang, 2024, Acta Materia Medica.

Current regulatory status in China of drugs withdrawn from the US FDA accelerated pathway: implications for regulation globally.

Xingxian Luo, Xin-Li Du, Yue Yang, 2024, The Lancet. Oncology.